Questions of ethical regulation of immunobiological therapy of some occupational lung diseases

Abstract

Objective. Taking into account a high prevalence of occupational pathology associated with the exposure of industrial aerosols, to analyze the principles of therapy used for patients with these diseases.

Materials and methods. The regulating medical documents, the data of preventive medical examinations as well as the principles of therapy applied for patients with occupational diseases, which are presented in scientific literarure, are analyzed.

Results. The role of harmful production factors in the formation of pneumoconiosis and alveolitis, which join the group of interstitial lung diseases (ILD), has been proved. The outcome of these occupational diseases is fibrosing alveolitis with the development of diffuse pulmonary fibrosis. In the treatment of ILD, immunobiological drugs (IBD) are used to suppress the immune processes selectively affecting the monoclonal antibodies, blocking of which interrupts inflammation and in 90 % of cases stops the further development of the disease.

Conclusions. The use of immunobiological drugs in clinical practice should be carried out within the framework of ethical and legal regulation between the patient and the doctor.

Keywords

interstitial lung diseases / immunobiological preparations / ethical and legal regulation of biomedical technologies

References

[1] Occupational diseases of the respiratory system: national guidelines. Ed. by N.F. Izmerov, A.G. Chuchalina. Moscow: GEOTAR-Media 2015; 792 (in Russian).

[2] Профессиональные заболевания органов дыхания: национальное руководство. Под ред. Н.Ф. Измерова, А.Г. Чучалина. М.: ГЭОТАР–Медиа 2015: 792.

[3] Gugis N.N., Plastinin B.G. Introduction of modern methods for ensuring labor protection and industrial safety. Metallurg 2011; 4: 23–26 (in Russian).

[4] Гугис Н.Н., Пластинин Б.Г. Внедрение современных методов обеспечения охраны труда и промышленной безопасности. Металлург 2011; 4: 23–26.

[5] Bazarova E.L., Fedoruk A.A., Roslaya N.A., Osherov I.S., Babenko A.G. Experience in assessing the occupational risk associated with the impact of industrial aerosols in the conditions of modernization of a metallurgical enterprise. Gigiena truda 2019; 1 (330): 38–45 (in Russian).

[6] Базарова Е.Л., Федорук А.А., Рослая Н.А., Ошеров И.С., Бабенко А.Г. Опыт оценки профессионального риска, связанного с воздействием промышленных аэрозолей, в условиях модернизации металлургического предприятия. Гигиена труда 2019; 1 (330): 38–45.

[7] Shlyapnikov D.M., Vlasova E.M., Pono¬mareva T.A. Respiratory diseases in workers of metallurgical production. Medicina truda i promyshlennaja jekologija 2012; 12: 16–19 (in Russian).

[8] Шляпников Д.М., Власова Е.М., Пономарева Т.А. Заболевания органов дыхания у работников металлургического производства. Медицина труда и промышленная экология 2012; 12: 16–19.

[9] Babanov S.A., Budash D.S. Modern approaches to the diagnosis of occupational bronchitis. Vrach 2016; 2: 14–16 (in Russian).

[10] Бабанов С.А., Будаш Д.С. Современные подходы к диагностике профессионального бронхита. Врач 2016; 2: 14–16.

[11] Vasilyeva O.S., Kravchenko N.Yu. Pneumoconiosis in the practice of the attending physician. Consilium medicum 2016; 18 (11): 39–45 (in Russian).

[12] Васильева О.С., Кравченко Н.Ю. Пневмокониоз в практике лечащего врача. Consilium medicum 2016; 18 (11): 39–45.

[13] Babanov S.A., Strizhakov L.A., Lebedeva M.V., Fomin V.V., Budash D.S., Baykova A.G. Pneumoconiosis: modern views. Terapevticheskij arhiv 2019; 91 (3): 107–113 (in Russian).

[14] Бабанов С.А., Стрижаков Л.А., Лебедева М.В., Фомин В.В., Будаш Д.С., Байкова А.Г. Пневмокониозы: современные взгляды. Терапевтический архив 2019; 91 (3): 107–113.

[15] Lysdal N.S., Mosbech N., Johansen J.D. Asthma and Respiratory Symptoms among Hairdressers in Denmark: Results from a Register Based Questionnaire Study. Am J Ind Med 2014; 57 (12): 1368–1376.

[16] Lysdal Н.S., Mosbech Н., Johansen J.D. Asthma and Respiratory Symptoms among Hairdressers in Denmark: Results from a Register Based Questionnaire Study. Am J Ind Med 2014; 57 (12): 1368–1376.

[17] Dudintseva N.V., Zhestkov A.V., Stulin V.V., Lotkov V.S. Prognostication of professional bronchial asthma development. Pul'monologija 2017; 27 (4): 484–489 (in Russian).

[18] Дудинцева Н.В., Жестков А.В., Стулин В.В., Лотков В.С. Прогнозирование развития профессиональной бронхиальной астмы. Пульмонология 2017; 27 (4): 484–489.

[19] Selman M., Pardo A. King T.E. Hypersensitivity Pneumonitis Insights in Diagnosis and Pathobiology. Am J RespirCrit Care Med 2012; 186 (4): 314–324.

[20] Selman M., Pardo A. King T.E. Hypersensitivity Pneumonitis Insights in Diagnosis and Pathobiology. Am J Respir Crit Care Med 2012; 186 (4): 314–324.

[21] Pereira C.A.C., Gimenez A., Kuranishi L, Storrer K. Chronic hypersensitivity рneumonitis. J Asthma Allergy 2016; 9: 171–181.

[22] Orlova G.P. Lung diseases caused by exogenous exposure to toxic and dust factors: Clinical and experimental study: abstract of the dissertation of the Doctor of Medical Sciences 2003; 29 (in Russian).

[23] Орлова Г.П. Заболевания легких, вызванные экзогенным воздействием токсико-пылевых факторов: клинико-эксперимен¬тальное исследование: автореф. дис. … д-ра мед. наук 2003: 29.

[24] Ilkovich M.M. Disseminated lung diseases. Moscow 2011; 480 (in Russian).

[25] Илькович М.М. Диссеминированные заболевания легких. М.: ГЭОТАР-Медиа 2011; 480.

[26] Orlova G.P., Surkova E.A., Lapin S.V. Markers of activity of exogenous interstitial lung diseases. Pul'monologija 2016; 26 (2): 180–185 (in Russian).

[27] Орлова Г.П., Суркова Е.А., Лапин С.В. Маркеры активности экзогенных интерстициальных заболеваний легких. Пульмонология 2016; 26 (2): 180–185.

[28] Du Bois R.M., Weycker D., Albera C., Bradford W.Z., Costabel U., Kartashov A., King T.E. Jr., Lancaster L., Noble P.W., Sahn S.A., Thomeer M., Valeyre D., Wells A.U. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. American Journal of Respiratory and Critical Care Medicine 2011; 84 (12): 1382–1389.

[29] Du Bois R.M., Weycker D., Albera C., Bradford W.Z., Costabel U., Kartashov A., King T.E. Jr., Lancaster L., Noble P.W., Sahn S.A., Thomeer M., Valeyre D., Wells A.U. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference/American Journal of Respiratory and Critical Care Medicine 2011; 84 (12): 1382–1389.

[30] Travis W.D., Costabel U., Hansell D.M., King T.E. Jr., Lynch D.A., Nicholson A.G., Ryerson C.J., Ryu J.H., Selman M., Wells A.U., Behr J., Bouros D., Brown K.K., Colby T.V., Collard H.R., Cordeiro C.R., Cottin V., Crestani B., Drent M., Dudden R.F., Egan J., Flaherty K., Hogaboam C., Inoue Y., Johkoh T., Kim D.S., Kitaichi M., Loyd J., Martinez F.J., Myers J., Protzko S., Raghu G., Richeldi L., Sverzellati N., Swigris J., Valeyre D.An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J RespirCrit Care Med 2013; 188 (6): 733–748.

[31] Travis W.D., Costabel U., Hansell D.M., King T.E. Jr., Lynch D.A., Nicholson A.G., Ryerson C.J., Ryu J.H., Selman M., Wells A.U., Behr J., Bouros D., Brown K.K., Colby T.V., Collard H.R., Cordeiro C.R., Cottin V., Crestani B., Drent M., Dudden R.F., Egan J., Flaherty K., Hogaboam C., Inoue Y., Johkoh T., Kim D.S., Kitaichi M., Loyd J., Martinez F.J., Myers J., Protzko S., Raghu G., Richeldi L., Sverzellati N., Swigris J., Valeyre D. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188 (6): 733–748.

[32] Respiratory epidemiology. ERS monograph. Editors I. Annesi-Maesano, B. Lundback, G. Viegi. Norwich, UK: PageBros 2014; 304.

[33] Respiratory epidemiology. ERS monograph. Editors I. Annesi-Maesano, B. Lundback, G. Viegi. Norwich, UK: Page Bros 2014; 304.

[34] Shostak N.A., Klimenko A.A., Kondrashov A.A. Interstitial lung diseases: key targets for therapy. Klinicist 2017; 11 (3–4): 10–16 (in Russian).

[35] Шостак Н.А., Клименко А.А., Кондрашов А.А. Интерстициальные заболевания легких: ключевые мишени для терапии. Клиницист 2017; 11 (3–4): 10–16.

[36] Federal Law No. 157 of 17.09.1998. On immunoprophylaxis of infectious diseases. Moscow 1998.

[37] ФЗ № 157 от 17.09.1998. Об иммунопрофилактике инфекционных болезней. М., 1998.

[38] Sgalla G., Iovene В., Calvello М., Ori М., Varone F., Richeldi L. Idiopathic pulmonary fibrosis: pathogenesis and management. Respiratory Research 2018; 19 (1): 32.

[39] Sgalla G., Iovene В.,Calvello М., Ori М., Varone F., Richeldi L. Idiopathic pulmonary fibrosis: pathogenesis and management. Respiratory Research 2018; 19 (1): 32.

[40] Petrov D.V.,Ovsyannikov N.V., Kapralov E.A., Kapustyan O.V. Interstitial lung diseases: the point of view of a practical doctor. Prakticheskaja pul'monologija 2014; (1): 34–38 (in Russian).

[41] Петров Д.В., Овсянников Н.В., Капралов Э.А., Капустьян О.В. Интерстициальные заболевания легких: точка зрения практического врача. Практическая пульмонология 2014; (1): 34–38.

[42] Adegunsoye А., Oldham J.M., Fernández Pérez E.R., Hamblin М., Patel N., Tener М., Bhanot D., Robinson L., Bullick S., Chen L., Hsu S., Churpek М., Hedeker D., Montner S., Chung J.H., Husain A.N., Noth I., Strek М.Е., Vij R. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Research 2017; 3: 00016-2017.

[43] Adegunsoye А., Oldham J.M., Fernández Pérez E.R., Hamblin М., Patel N., Tener М., Bhanot D., Robinson L., Bullick S., Chen L., Hsu S., Churpek М., Hedeker D., Montner S., Chung J.H., Husain A.N., Noth I., Strek М.Е., Vij R. Out come sofimmunosup pressive therapy in chroni chypersensitivity pneumonitis. ERJ Open Research 2017; 3: 00016–2017.

[44] Raghu G., Rochwerg B., Zhang Y., Garcia С.А.С., Azuma А., Behr J., Brozek J.L.,Collard H.R., Cunningham W., Homma S., Johkoh Т., Martinez F.J., Myers J., Protzko S.L., Richeldi L., Rind D., Selman М., Theodore А., Wells A.U., Hoogsteden Н.,Schunemann H.J. ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015 [cited 2017 May 29]; 192 (2): e3–e19.

[45] Raghu G., Rochwerg B., Zhang Y., GarciaС.А.С., Azuma А., Behr J., Brozek J.L., Collard H.R., Cunningham W., Homma S., Johkoh Т., Martinez F. J., Myers J., Protzko S.L., Richeldi L., Rind D., Selman М., Theodore А., Wells A.U., Hoogsteden Н., Schunemann H.J. ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: anupdate of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015 [cited 2017 May 29]; 192 (2): e3–e19.

[46] Lunardi F.Ph.D., Pezzuto F., Vuljan S.E., Calabrese F. Idiopathic Pulmonary Fibrosis and Antifibrotic Treatments Focus on Experimental Studies. Arch Pathol Lab Med 2018; 142: 1090–1097.

[47] Wollin L., Distler J.H.W., Redente E.F., Riches D.W.H., Stowasser S., Schlenker-Herceg R., Maher T.M., Kolb М. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. European Respiratory Journal 2019; 54: 1900161.

[48] Wollin L., Distler J.H.W., Redente E.F., Riches D.W.H., Stowasser S., Schlenker-Herceg R., Maher T.M., Kolb М. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. European Respiratory J 2019; 54: 1900161.

[49] Terpigorev S.A., Belevsky A.S. Efficacy and safety of pirfenidone in patients with idiopathic pulmonary fibrosis: data from multicenter and local studies. Prakticheskaja pul'monologija 2019; 3: 56–59 (in Russian).

[50] Терпигорев С.А., Белевский А.С. Эффективность и безопасность пирфенидона у больных идиопатическим легочным фиброзом: данные многоцентровых и локальных исследований. Практическая пульмонология 2019; 3: 56–59.

[51] Kim E.S., Keating. G.M. Pirfenidone: a review of its use in idiopathic pulmonary fibrosis. Drugs 2015; 75: 219–230.

[52] Averyanov A.V., Sotnikova A.G. Prospects of cell technologies in the treatment of idiopathic pulmonary fibrosis. Prakticheskaja pul'monologija 2019; 2: 43–44 (in Russian).

[53] Аверьянов А.В., Сотникова А.Г. Перспективы клеточных технологий в лечении идиопатического легочного фиброза. Практическая пульмонология 2019; 2: 43–44.

[54] King T.E.Jr., Bradford W.Z., Castro-Bernardini S., Fagan E.A., Glaspole I., Glassberg M.K., Gorina E., Hopkins P.M., Kardatzke D., Lancaster L., Lederer D.J., Nathan S.D., Pereira C.A., Sahn S.A., Sussman R., Swigris J.J., Noble P.W. ASCENDStudyGroup. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. The New England J of Medicine 2014; 370 (22): 2083–2092.

[55] King T.E. Jr., Bradford W.Z., Castro-Bernardini S., Fagan E.A., Glaspole I., Glas¬sberg M.K., Gorina E., Hopkins P.M., Kardatzke D., Lancaster L., Lederer D.J., Nathan S.D., Pereira C.A., Sahn S.A., Sussman R., Swigris J.J., Noble P.W. ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. The New England J of Medicine 2014; 370 (22): 2083–2092.

[56] Wiesel A.A., Belevsky A.S. Modern aspects of treatment of idiopathic pulmonary fibrosis. Prakticheskaja pul'monologija 2017; 2: 93–98 (in Russian).

[57] Визель А.А., Белевский А.С. Современные аспекты лечения идиопатического легочного фиброза. Практическая пульмонология 2017; 2: 93–98.

[58] Van Deursen J.M. The role of senescent cell sin ageing. Nature 2014; 509: 439–446.

[59] Van Deursen J.M. The role of senescent cells in ageing. Nature 2014; 509: 439–446.

[60] Agassandian M., Tedrowa J.R., Sem¬brata J., Kassa D.J., Zhanga Y., Goncharovab Е.А., Kaminskie N., Mallampallib R.K., Vuga L.J. VCAM-1 is a TGF-beta1 inducible gene upregulated in idiopathic pulmonary fibrosis. Cell Signal 2015; 27: 2467–2473.

[61] Agassandian M., Tedrowa J.R., Sembrata J., Kassa D.J., Zhanga Y., Goncha¬rovab Е.А., Kaminskie N., Mallampallib R.K., Vuga L.J. VCAM-1 is a TGF-beta1 inducible gene upregulated in idiopathic pulmonary fibrosis. Cell Signal 2015; 27: 2467–2473.

[62] Yanai H., Shteinberg А., Porat Z., Budovsky А., Braiman А., Zeische R., Fraifeld V.E.Cellular senescence-like features of lung fibroblasts derived from idiopathic pulmonary fibrosis patients. Aging (Albany NY) 2015; 7: 664–672.

[63] Yanai H., Shteinberg А., Porat Z., Budovsky А., Braiman А., Zeische R., Fraifeld V.E. Cellular senescence-like features of lung fibroblasts derived from idiopathic pulmonary fibrosis patients. Aging (Albany NY); 2015; 7: 664–672.

[64] Schafer M.J., White Т.А., Iijima К., Haak A.J., Ligresti G., Atkinson E.J., Oberg A.L., Birch J., Salmonowicz Н., Zhu Y., Mazula D.L., Brooks R.W., Fuhrmann-Stroissnigg Н., Pirtskhalava Т., Prakash Y.S., Tchkonia Т., Robbins P.D., Aubry М.С., Passos J.F., Kirkland J.L., Tschumperlin D.J., Kita Н., LeBrasseur N.K. Cellular senescence mediates fibrotic pulmonary disease. Published 2017; 8: 14532.

[65] Schafer M.J., White Т.А., Iijima К., Haak A.J., Ligresti G., Atkinson E.J., Oberg A.L., Birch J., Salmonowicz Н., Zhu Y., Mazula D.L., Brooks R.W., Fuhrmann-Stroissnigg Н., Pirtskha¬lava Т., Prakash Y.S., Tchkonia Т., Robbins P.D., Aubry М.С., Passos J.F., Kirkland J.L., Tschum¬perlin D.J., Kita Н., Le Brasseur N.K. Cellular senescence mediates fibrotic pulmonary disease. Published 2017; 8: 14532.

RIGHTS & PERMISSIONS

Shpagina L.A., Panacheva L.A., Zolotukhina E.V.